The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fridkis-Hareli, M.
Right arrow Articles by Strominger, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fridkis-Hareli, M.
Right arrow Articles by Strominger, J. L.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
The Journal of Immunology, 1998, 160: 4386-4397.
Copyright © 1998 by The American Association of Immunologists

Promiscuous Binding of Synthetic Copolymer 1 to Purified HLA-DR Molecules1

Masha Fridkis-Hareli and Jack L. Strominger2

Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA 02138

Copolymer 1 (Cop 1) is a random synthetic amino acid copolymer of L-alanine, L-glutamic acid, L-lysine, and L-tyrosine, effective both in suppression of experimental allergic encephalomyelitis and in the treatment of relapsing forms of multiple sclerosis. Cop 1 binds promiscuously and very efficiently to living APCs of various HLA haplotypes. In the present study, a substantial part of the whole mixture of random polypeptides that compose Cop 1 was shown to bind to purified human HLA-DR1, DR2, and DR4 with high affinity in a temperature- and time (and, in the case of DR4, pH)-dependent manner, and was competitively inhibited by DR-restricted peptides, but not by peptide derivatives that bind with low affinity. Bacterial superantigens inhibited Cop 1 binding only at very high concentrations. The formation of the Cop 1-DR1 complex was also shown by SDS-PAGE. These findings represent the first direct evidence for interactions of Cop 1 with purified DR molecules, and suggest that its effectiveness in experimental allergic encephalomyelitis and multiple sclerosis may be directly related to its binding in the groove of HLA-DR proteins.




This article has been cited by other articles:


Home page
 Mult SclerHome page
A. Hestvik, G Skorstad, D. Price, F Vartdal, and T Holmoy
Multiple sclerosis: glatiramer acetate induces anti-inflammatory T cells in the cerebrospinal fluid
Multiple Sclerosis, July 1, 2008; 14(6): 749 - 758.
[Abstract] [PDF]

Home page
 Mult SclerHome page
C Iarlori, D Gambi, A Lugaresi, A Patruno, M Felaco, M Salvatore, L Speranza, and M Reale
Reduction of free radicals in multiple sclerosis: effect of glatiramer acetate (Copaxone(R))
Multiple Sclerosis, July 1, 2008; 14(6): 739 - 748.
[Abstract] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. N. H. Stern, Z. Illes, J. Reddy, D. B. Keskin, M. Fridkis-Hareli, V. K. Kuchroo, and J. L. Strominger
Peptide 15-mers of defined sequence that substitute for random amino acid copolymers in amelioration of experimental autoimmune encephalomyelitis
PNAS, February 1, 2005; 102(5): 1620 - 1625.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. Sela and E. Mozes
Therapeutic vaccines in autoimmunity
PNAS, October 5, 2004; 101(suppl_2): 14586 - 14592.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. N. H. Stern, Z. Illes, J. Reddy, D. B. Keskin, E. Sheu, M. Fridkis-Hareli, H. Nishimura, C. F. Brosnan, L. Santambrogio, V. K. Kuchroo, et al.
Amelioration of proteolipid protein 139-151-induced encephalomyelitis in SJL mice by modified amino acid copolymers and their mechanisms
PNAS, August 10, 2004; 101(32): 11743 - 11748.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
Z. Illes, J. N. H. Stern, J. Reddy, H. Waldner, M. P. Mycko, C. F. Brosnan, S. Ellmerich, D. M. Altmann, L. Santambrogio, J. L. Strominger, et al.
Modified amino acid copolymers suppress myelin basic protein 85-99-induced encephalomyelitis in humanized mice through different effects on T cells
PNAS, August 10, 2004; 101(32): 11749 - 11754.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
H. H. Salama, J. Hong, Y. C. Q. Zang, A. El-Mongui, and J. Zhang
Blocking effects of serum reactive antibodies induced by glatiramer acetate treatment in multiple sclerosis
Brain, December 1, 2003; 126(12): 2638 - 2647.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
P. L. Vieira, H. C. Heystek, J. Wormmeester, E. A. Wierenga, and M. L. Kapsenberg
Glatiramer Acetate (Copolymer-1, Copaxone) Promotes Th2 Cell Development and Increased IL-10 Production Through Modulation of Dendritic Cells
J. Immunol., May 1, 2003; 170(9): 4483 - 4488.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
S Chabot, F P Yong, D M Le, L M Metz, T Myles, and V W Yong
Cytokine production in T lymphocyte-microglia interaction is attenuated by glatiramer acetate: a mechanism for therapeutic efficacy in multiple sclerosis
Multiple Sclerosis, August 1, 2002; 8(4): 299 - 306.
[Abstract] [PDF]

Home page
 Int ImmunolHome page
R. Maron, A. J. Slavin, E. Hoffmann, Y. Komagata, and H. L. Weiner
Oral tolerance to copolymer 1 in myelin basic protein (MBP) TCR transgenic mice: cross-reactivity with MBP-specific TCR and differential induction of anti-inflammatory cytokines
Int. Immunol., February 1, 2002; 14(2): 131 - 138.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
C. Fusco, V. Andreone, G. Coppola, V. Luongo, F. Guerini, E. Pace, C. Florio, G. Pirozzi, R. Lanzillo, P. Ferrante, et al.
HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis
Neurology, December 11, 2001; 57(11): 1976 - 1979.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Bar-Or, E. M. L Oliveira, D. E. Anderson, J. I. Krieger, M. Duddy, K. C. O'Connor, and D. A. Hafler
Immunological Memory: Contribution of Memory B Cells Expressing Costimulatory Molecules in the Resting State
J. Immunol., November 15, 2001; 167(10): 5669 - 5677.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
P. J. Ruiz, J. J. DeVoss, L.-V. T. Nguyen, P. P. Fontoura, D. L. Hirschberg, D. J. Mitchell, K. C. Garcia, and L. Steinman
Immunomodulation of Experimental Autoimmune Encephalomyelitis with Ordered Peptides Based on MHC-TCR Binding Motifs
J. Immunol., September 1, 2001; 167(5): 2688 - 2693.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
M Chen, B Gran, K Costello, K Johnson, R Martin, and S Dhib-Jalbut
Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS
Multiple Sclerosis, August 1, 2001; 7(4): 209 - 219.
[Abstract] [PDF]

Home page
 NeurologyHome page
O. Neuhaus, C. Farina, H. Wekerle, and R. Hohlfeld
Mechanisms of action of glatiramer acetate in multiple sclerosis
Neurology, March 27, 2001; 56(6): 702 - 708.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
A WINDHAGEN, S MANIAK, S MARCKMANN, A WILKENING, R-B LINDERT, F HEIDENREICH, and R BLASCZYK
Lymphadenopathy in patients with multiple sclerosis undergoing treatment with glatiramer acetate
J. Neurol. Neurosurg. Psychiatry, March 1, 2001; 70(3): 415 - 416.
[Full Text]

Home page
 Proc. Natl. Acad. Sci. USAHome page
H. Schori, J. Kipnis, E. Yoles, E. WoldeMussie, G. Ruiz, L. A. Wheeler, and M. Schwartz
Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: Implications for glaucoma
PNAS, March 1, 2001; (2001) 41609498.
[Abstract] [Full Text]

Home page
 Infect. Immun.Home page
K. Visvanathan, A. Charles, J. Bannan, P. Pugach, K. Kashfi, and J. B. Zabriskie
Inhibition of Bacterial Superantigens by Peptides and Antibodies
Infect. Immun., February 1, 2001; 69(2): 875 - 884.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
S. Ragheb, S. Abramczyk, D. Lisak, and R. Lisak
Long-term therapy with glatiramer acetate in multiple sclerosis: effect on T-cells
Multiple Sclerosis, February 1, 2001; 7(1): 43 - 47.
[Abstract] [PDF]

Home page
 J. Immunol.Home page
P. W. Duda, J. I. Krieger, M. C. Schmied, C. Balentine, and D. A. Hafler
Human and Murine CD4 T Cell Reactivity to a Complex Antigen: Recognition of the Synthetic Random Polypeptide Glatiramer Acetate
J. Immunol., December 15, 2000; 165(12): 7300 - 7307.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
B. Gran, L. R. Tranquill, M. Chen, B. Bielekova, W. Zhou, S. Dhib-Jalbut, and R. Martin
Mechanisms of immunomodulation by glatiramer acetate
Neurology, December 12, 2000; 55(11): 1704 - 1714.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. O. Tzianabos, R. W. Finberg, Y. Wang, M. Chan, A. B. Onderdonk, H. J. Jennings, and D. L. Kasper
T Cells Activated by Zwitterionic Molecules Prevent Abscesses Induced by Pathogenic Bacteria
J. Biol. Chem., March 15, 2000; 275(10): 6733 - 6740.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
O. Rotzschke, K. Falk, J. Mack, J. M. Lau, G. Jung, and J. L. Strominger
Conformational variants of class II MHC/peptide complexes induced by N- and C-terminal extensions of minimal peptide epitopes
PNAS, June 22, 1999; 96(13): 7445 - 7450.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
M. Fridkis-Hareli, R. Aharoni, D. Teitelbaum, R. Arnon, M. Sela, and J. L. Strominger
Binding of random copolymers of three amino acids to class II MHC molecules
Int. Immunol., May 1, 1999; 11(5): 635 - 641.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Fridkis-Hareli, J. M. Neveu, R. A. Robinson, W. S. Lane, L. Gauthier, K. W. Wucherpfennig, M. Sela, and J. L. Strominger
Binding Motifs of Copolymer 1 to Multiple Sclerosis- and Rheumatoid Arthritis-Associated HLA-DR Molecules
J. Immunol., April 15, 1999; 162(8): 4697 - 4704.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
H. L. Weiner
Oral tolerance with Copolymer 1 for the treatment of multiple sclerosis
PNAS, March 30, 1999; 96(7): 3333 - 3335.
[Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
R. Aharoni, D. Teitelbaum, R. Arnon, and M. Sela
Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking
PNAS, January 19, 1999; 96(2): 634 - 639.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
K. J. Smith, J. Pyrdol, L. Gauthier, D. C. Wiley, and K. W. Wucherpfennig
Crystal Structure of HLA-DR2 (DRA*0101, DRB1*1501) Complexed with a Peptide from Human Myelin Basic Protein
J. Exp. Med., October 19, 1998; 188(8): 1511 - 1520.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. Fridkis-Hareli, E. F. Rosloniec, L. Fugger, and J. L. Strominger
Synthetic amino acid copolymers that bind to HLA-DR proteins and inhibit type II collagen-reactive T cell clones
PNAS, October 13, 1998; 95(21): 12528 - 12531.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
H. Schori, J. Kipnis, E. Yoles, E. WoldeMussie, G. Ruiz, L. A. Wheeler, and M. Schwartz
Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: Implications for glaucoma
PNAS, March 13, 2001; 98(6): 3398 - 3403.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1998 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1998 by The American Association of Immunologists, Inc. All rights reserved.